HSPA5 and prostate carcinoma: In conclusion, conjugation of a GRP78 inhibitor to [177Lu]Lu–iPSMA improves the radionuclide internalization and cytotoxicity in prostate cancer cells, suggesting that the bispecific radiopharmaceutical is a promising strategy in prostate cancer treatment.